AbbVie: H1 2025 Earnings Strengthen Case For Targeting Gilgamesh Acquisition

Core Insights - AbbVie Inc. reported Q2 2025 earnings showcasing strong performance from Skyrizi and Rinvoq, which generated $6.4 billion in global sales, representing 41% of the company's total revenues for the quarter [1] Financial Performance - Skyrizi and Rinvoq's combined sales of $6.4 billion highlight their significant contribution to AbbVie's revenue stream [1] - The performance of these products indicates a robust market presence and potential for continued growth in the future [1] Product Analysis - Both Skyrizi and Rinvoq are demonstrating strong market performance, suggesting their effectiveness and acceptance in the healthcare market [1]